Peruvian oncologists renew cervical screening calls, as local data show 30% cancer rate
This article was originally published in Clinica
Almost a third of women screened for cervical cancer at a centre serving a Peruvian suburb were found to have the disease. So said the health ministry, citing an assessment of data from the first 1,000 women screened (by Pap smear) this year in the Lima Este area of the capital. Cancer experts involved in the programme are calling on all sexually-active women to come forward for testing "annually or at least once every three years". Women aged 30-49 years in Peru are being asked to undergo screening annually, "as a matter of course". Cervical cancer is the second-leading cause of death among Peruvian women.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.